<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2023.1266668</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Polyreactivity of antibodies from different B-cell subpopulations is determined by distinct sequence patterns of variable region</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lecerf</surname>
<given-names>Maxime</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/387666"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lacombe</surname>
<given-names>Robin V.</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Dimitrov</surname>
<given-names>Jordan D.</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1325935"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Centre de Recherche des Cordeliers, INSERM, CNRS, Sorbonne Universit&#xe9;</institution>, <addr-line>Universit&#xe9; Paris Cit&#xe9;, Paris</addr-line>, <country>France</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Juan C. Almagro, GlobalBio Inc, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Heinz Kohler, Retired, Carlsbad, CA, United States; Michael Anthony Moody, Duke University, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Jordan D. Dimitrov, <email xlink:href="mailto:jordan.dimitrov@sorbonne-universite.fr">jordan.dimitrov@sorbonne-universite.fr</email>, <email xlink:href="mailto:jordan.dimitrov@crc.jussieu.fr">jordan.dimitrov@crc.jussieu.fr</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>11</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1266668</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>07</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>10</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Lecerf, Lacombe and Dimitrov</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Lecerf, Lacombe and Dimitrov</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>An antibody molecule that can bind to multiple distinct antigens is defined as polyreactive. In the present study, we performed statistical analyses to assess sequence correlates of polyreactivity of &gt;600 antibodies cloned from different B-cell types of healthy humans. The data revealed several sequence patterns of variable regions of heavy and light immunoglobulin chains that determine polyreactivity. The most prominent identified patterns were increased number of basic amino acid residues, reduced frequency of acidic residues, increased number of aromatic and hydrophobic residues, and longer length of CDR L1. Importantly, our study revealed that antibodies isolated from different B-cell populations used distinct sequence patterns (or combinations of them) for polyreactive antigen binding. Furthermore, we combined the data from sequence analyses with molecular modeling of selected polyreactive antibodies and demonstrated that human antibodies can use multiple pathways for achieving antigen-binding promiscuity. These data reconcile some contradictions in the literature regarding the determinants of antibody polyreactivity. Moreover, our study demonstrates that the mechanism of polyreactivity of antibodies evolves during immune response and might be tailored to specific functional properties of different B-cell compartments. Finally, these data can be of use for efforts in the development and engineering of therapeutic antibodies.</p>
</abstract>
<kwd-group>
<kwd>antibodies</kwd>
<kwd>variable regions</kwd>
<kwd>antibody polyreactivity</kwd>
<kwd>sequence analyses</kwd>
<kwd>molecular modeling</kwd>
</kwd-group>
<contract-sponsor id="cn001">European Research Council<named-content content-type="fundref-id">10.13039/501100000781</named-content>
</contract-sponsor>
<counts>
<fig-count count="7"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="76"/>
<page-count count="15"/>
<word-count count="7897"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>B Cell Biology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>An antibody (Ab) molecule that can interact with multiple unrelated antigens is referred to as polyreactive (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B3">3</xref>). Polyreactive Abs are normal constituents of immune repertoires and have important functions. For example, they participate in the first line of defense against pathogens (<xref ref-type="bibr" rid="B4">4</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>) and contribute to establishing mutualistic equilibrium between the host and microbiome (<xref ref-type="bibr" rid="B7">7</xref>&#x2013;<xref ref-type="bibr" rid="B9">9</xref>). Notably, many of broadly neutralizing Abs against HIV-1 and influenza virus display antigen-binding polyreactivity (<xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B16">16</xref>). Polyreactive antibodies also participate in the clearance of apoptotic cells and damaged macromolecules (<xref ref-type="bibr" rid="B17">17</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>). Nevertheless, polyreactivity is considered a negative trait for therapeutic Abs (<xref ref-type="bibr" rid="B20">20</xref>). It can cause deterioration of the pharmacokinetics of therapeutic Abs and poses a risk of undesirable effects (<xref ref-type="bibr" rid="B20">20</xref>). Moreover, polyreactivity correlates with other liabilities of Abs, such as the tendency for self-association (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>Since the discovery of polyreactive Abs, research efforts have been dedicated to unraveling its molecular basis. These efforts were boosted following the identification of polyreactivity as a developability risk for therapeutic Abs. Many features of variable (V) domains have been associated with polyreactivity, but controversial results are often reported in the literature. Thus, polyreactive Abs were shown to contain an elevated number of positively charged amino acid residues in their CDR H3 (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B23">23</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>). The presence of patches of positive charges on the molecular surface of the antigen-binding site or unbalanced distribution of charges has also been associated with polyreactivity of Abs (<xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>). Analyses of synthetic Ab libraries revealed that some hydrophobic and aromatic residues in CDR H3 could also contribute to polyreactivity (<xref ref-type="bibr" rid="B34">34</xref>). Conversely, a recent study of large repertoires of mouse and human Abs found a tendency for neutrality, or absence of a particular predominance of charges or hydrophobicity, in antigen-binding sites of polyreactive Abs (<xref ref-type="bibr" rid="B35">35</xref>). Polyreactivity was also associated with a longer CDR H3 loop (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>) and a higher tendency of this loop to form &#x3b2;-sheets (<xref ref-type="bibr" rid="B38">38</xref>). Other works, however, failed to detect differences in the size of CDR H3 between polyreactive and monoreactive Abs (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B35">35</xref>). A global trait of V domains that has been related to promiscuity is conformational dynamics (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Many studies demonstrated that paratopes of polyreactive Abs have increased conformational flexibility (<xref ref-type="bibr" rid="B40">40</xref>&#x2013;<xref ref-type="bibr" rid="B48">48</xref>). Nonetheless, there are reports demonstrating that some Abs can display polyreactivity without substantial conformational dynamics (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>The conflicting results about the role of specific sequence or molecular attributes of Ab polyreactivity imply that there is still incomplete understanding of how Ab molecules attain promiscuous antigen binding. Several reasons can explain the conflicting results in the literature. They may be the result of the use of different experimental assays for assessment of Ab polyreactivity, the use of different statistical methods for analyses of data, the use of limited sets of Abs, evaluation of polyreactivity of Abs from different species (human vs. mouse), and assessment of polyreactivity of Ab repertoires biased by selection for a particular antigen specificity. They may also reflect the existence of multiple mechanisms of polyreactivity.</p>
<p>Recently, we implemented a sequence analyses approach where the polyreactivity of clinical-stage therapeutic Abs was correlated with the frequency of each amino acid residue, type of residues, and some global features (length of CDRs, number of somatic mutations) of V domains (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>). These data revealed specific sequence traits associated with natural or induced by pro-oxidative substances polyreactivity in therapeutic Abs. We anticipated that application of the same approach for analyses of large human Ab repertoires would allow deciphering determinants of polyreactivity.</p>
<p>We used data sets from two recent studies (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B37">37</xref>) and analyzed the sequence patterns that determine the polyreactivity in human Ab repertoires. Importantly, we applied the analyses to subcategories of Abs identified on the basis of the B-cell type from which they were cloned. We also applied molecular modeling to predict the structure of top polyreactive Abs from each category. Our data revealed several unique sequence patterns determining the polyreactivity of human Abs. Notably, polyreactivity of Abs from different B-cell subpopulations was determined by distinct sequence patterns of V domains. Our study also showed that human Ab might use various molecular mechanisms of polyreactivity. These results might have important repercussions for understanding the mechanism and biological functions of polyreactive Abs.</p>
</sec>
<sec id="s2" sec-type="results">
<title>Results</title>
<sec id="s2_1">
<title>Human monoclonal Abs subjected to analyses</title>
<p>We used the data sets from two studies where monoclonal Abs were cloned from different subpopulations of healthy human B cells. Thus, we analyzed sequences of 398 Abs characterized in the study of Shehata et&#xa0;al. (<xref ref-type="bibr" rid="B27">27</xref>). These Abs were cloned from naive, IgM memory, and IgG memory B cells and from long-lived plasma cells (LLPCs). In addition, we evaluated sequence correlates of polyreactivity of 240 monoclonal Abs cloned from IgA memory B cells, described in the study of Prigent et&#xa0;al. (<xref ref-type="bibr" rid="B37">37</xref>). In both studies, Abs were cloned without selection for a particular antigenic specificity and expressed exclusively as IgG1 for functional analyses. Of note, the two studies used different approaches for the estimation of Ab polyreactivity. Thus, Shehata et&#xa0;al. used a technique referred to as polyspecificity reagent assay (PSR), where Ab reactivity to proteins available in human cell lysate is measured by flow cytometry and presented as a gradually increasing numeric score (<xref ref-type="bibr" rid="B27">27</xref>). Prigent et&#xa0;al. assessed Ab polyreactivity by ELISA (<xref ref-type="bibr" rid="B37">37</xref>). To use the semi-quantitative data presented in the work of Prigent et&#xa0;al. in our correlation analyses, we first assigned numeric scores of reactivity based on the number of recognized antigens by a given Ab (see <italic>Methods</italic>).</p>
<p>In previous works, V region sequence patterns that determined polyreactivity were evaluated by using pools of Abs that originate from different B-cell subpopulations. Moreover, some of these studies used Abs directed to pathogens (influenza virus or HIV-1) or Abs designed to be used as therapeutics. Here, we aimed to assess the sequence traits of V<sub>H</sub> and V<sub>L</sub> regions that correlate with Ab polyreactivity using Abs without pre-defined antigen specificity. We also considered it important, in addition to bulk analyses, to segregate the Abs as based on their origin (B-cell types from which they were isolated) and perform the statistical analyses individually.</p>
</sec>
<sec id="s2_2">
<title>Correlation analyses of sequence features of V<sub>H</sub> and V<sub>L</sub> regions determining the polyreactivity of Abs from different B-cell subpopulations</title>
<p>We applied Spearman non-parametric correlation analysis to assess the sequence patterns of V<sub>H</sub> and V<sub>L</sub> domains associated with polyreactivity of human Abs. The obtained data from correlation analysis for the V<sub>H</sub> domain are depicted in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>. These data demonstrated that Ab polyreactivity significantly correlates with increased or reduced frequencies of certain amino acid residues in the V domain. Strikingly, distinct patterns of significant correlations were observed between the groups of Abs originating from different B-cell subpopulations (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Thus, polyreactivity negatively correlated with the number of V<sub>H</sub> somatic mutations for Abs originating from IgM+ B cells, but no significant correlation was found in other groups. In addition, a positive correlation between the length of CDR H3 and polyreactivity was observed only for Abs cloned from IgA+ B cells. The polyreactivity of Abs from three B-cell subtypes&#x2014;naive, IgG+ memory and plasma cells, correlated with the presence of a higher number of basic amino acid residues (Arg, His, and Lys) in CDR H2 (naive B cells and LLPC) and CDR H3 (IgG+ memory B cells) and within entire V<sub>H</sub> region (LLPC). However, no increased number of basic amino acid residues in any part of the V region was associated with the polyreactivity of Abs isolated from IgM+ and IgA+ memory B cells. Reduced number of acidic amino acid residues (Asp and Glu) in the entire V<sub>H</sub> region or in CDR H1 and CDR H2 was associated with a higher polyreactivity in the case of Abs cloned from all types of memory B cells but not from naive B cells and LLPC (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Abs cloned from each B-cell subpopulation demonstrated unique patterns of positive or negative correlates of polyreactivity with the number of polar amino acid residues in V<sub>H</sub> domain. The presence of polar residues was especially important for determining the polyreactivity of IgG+ memory B cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Thus, a higher number of polar amino acids (as a physiochemical category) in CDR H1 and H2 and in the entire V<sub>H</sub> was positively correlated with promiscuous antigen binding of Abs. Statistically significant correlations were also found for the number of Gln residues in the entire V<sub>H</sub> and Cys residues in CDR H3 (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Contrary, polyreactivity negatively correlated with the presence of Thr in CDR H1 in Abs cloned from naive B cells. Our data demonstrated that the polyreactivity of Abs isolated from IgA+ memory B cells significantly correlated with the presence of different hydrophobic residues (Val, Ile, Leu, and Met) in the entire V<sub>H</sub> region or in CDR H1 and H3 loops (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). This prominent pattern was not observed in Abs isolated from other types of B cells. On the contrary, the polyreactivity of Abs from IgG+ memory B cells was negatively correlated with the number of hydrophobic amino acids (as a physiochemical category) in the entire V<sub>H</sub> domain or CDR H2. The increased number of hydrophobic residues in V<sub>H</sub> of Abs isolated from IgA+ B cells resulted in a significant correlation of polyreactivity with augmented hydrophobicity index (GRAVY) of all CDR loops and entire V<sub>H</sub> domain (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Notable patterns of sequence correlations were also observed regarding the presence of aromatic amino acid residues in V<sub>H</sub> domain. Thus, the number of aromatic amino acids (as a group) or of Tyr in V<sub>H</sub> or in CDR H3 positively correlated with enhanced polyreactivity of Abs cloned from IgM+ B cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Positive correlation between polyreactivity and aromatic amino acids was also found for Abs from LLPC, but in this case, the presence of any aromatic residues in CDR H1 or Phe in CDR H3 reached significance. Notably, reverse tendencies were observed for Abs isolated from IgG+ and IgA+ B cells, where the presence of aromatic residues or Phe negatively correlated with the antigen-binding polyreactivity (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). The number of Gly residues significantly correlated with polyreactivity only for Abs that originated from naive B cells. Thus, a lower number of Gly in the V<sub>H</sub> region and CDR H2 was associated with higher polyreactivity. However, a reverse tendency was observed for Gly residues in the case of CDR H1 (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Correlation analyses of polyreactivity of human Abs cloned from different B-cell subpopulations with sequence characteristics of V<sub>H</sub> domain. The heat maps present correlation coefficient (&#x3c1;) obtained by Spearman&#x2019;s rank analyses of sequences characteristics of V<sub>H</sub> domains (e.g., frequency of individual amino acid residues, type of residues, length of CDR H loops, mutation loads, and hydrophobicity GRAVY index) with the extent of the antigen-binding polyreactivity. Abs were grouped according to their B-cell origin naive, IgM+ memory, IgG+ memory, IgA+ memory, and long-lived plasma cells. The blue color signifies a negative correlation; the red color signifies a positive correlation. The statistical significance (p-value) is indicated by a circle. Open circle p &lt; 0.05; semi-closed circle p &lt; 0.01, and closed circle p &lt; 0.005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1266668-g001.tif"/>
</fig>
<p>Our data also revealed that sequence features of framework regions (FW) of V<sub>H</sub> can also contribute to the polyreactivity of Abs. Importantly, we found that the patterns of significance in FW regions also depended on the origin of Abs (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). As FW regions are less frequently subjected to somatic mutations, the observed differences may reflect biased use of V<sub>H</sub> genes in the case of Abs with extended antigen-binding polyreactivity.</p>
<p>Our analyses showed that several sequence features of the V<sub>L</sub> domain also correlate with polyreactivity of Abs (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). Again, different sequence patterns of correlation were detected depending on the B-cell origin of the studied Abs, albeit these differences were less prominent as compared to those observed in V<sub>H</sub> (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1</bold>
</xref>, <xref ref-type="fig" rid="f2">
<bold>2</bold>
</xref>). An important observation from these data is the presence of a positive correlation between the size of the entire V<sub>L</sub> region or CDR L1 and polyreactive antigen binding in Abs cloned from three different B-cell subpopulations, naive, IgG+ memory, and LLPC. Although the data did not reach statistical significance, the same tendency was present in the case of IgM+ memory B cells. These data suggest that the length of CDR L1 is an important determinant of polyreactivity of Abs. Interestingly, statistical significance was present between the lower numbers of Gln residues in CDR L1 and antigen-binding polyreactivity in all B-cell subpopulations except in naive B cells (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). Of note, this CDR L1 is characterized by the highest variability in length among CDRs in V<sub>L</sub> region. Another common sequence trait positively correlating with polyreactivity of different B-cell subpopulations is the presence of a higher number of aromatic amino acids in all CDR loops. Such correlation reached significance for Abs cloned from naive-, IgG+, and LLPC (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). An important general observation of the correlation analyses of V<sub>L</sub> domain is that the region that has the most significant capacity to determine the promiscuous antigen binding of Abs, from different B-cell subpopulations is CDR L1 (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). Similarly, as the observation for V<sub>H</sub>, the sequence features in FW regions correlating with polyreactivity of Abs showed particularities as dependent on the B-cell type from which Abs were cloned.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Correlation analyses of polyreactivity of human Abs cloned from different B-cell subpopulations with sequence characteristics of V<sub>L</sub> domain. The heat maps present correlation coefficient (&#x3c1;) obtained by Spearman&#x2019;s rank analyses of sequences characteristics of V<sub>L</sub> domains (e.g., frequency of individual amino acid residues, type of residues, length of CDR L loops, mutation loads, and hydrophobicity GRAVY index) with the extent of the antigen-binding polyreactivity. Abs were grouped according to their B-cell origin naive, IgM+ memory, IgG+ memory, IgA+ memory, and long-lived plasma cells. The blue color signifies a negative correlation; the red color signifies a positive correlation. The statistical significance (p-value) is indicated by a circle. Open circle p &lt; 0.05; semi-closed circle p &lt; 0.01, and closed circle p &lt; 0.005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1266668-g002.tif"/>
</fig>
<p>Taken together, the data from Spearman correlation analyses of V<sub>H</sub> and V<sub>L</sub> performed on Abs categorized based on their B-cell origin unravel numerous sequence patterns significantly correlating with the antigen-binding promiscuity. Notably, unique patterns were present in different groups of Abs.</p>
</sec>
<sec id="s2_3">
<title>Compatibility between Ab repertoires</title>
<p>It is noteworthy that the Abs cloned from IgA+ memory B cells (n=240) were analyzed for polyreactivity by ELISA (<xref ref-type="bibr" rid="B13">13</xref>), whereas the binding promiscuity of the rest of Abs (n=398) was assessed by PSR assay (<xref ref-type="bibr" rid="B27">27</xref>). We realized that the use of two distinct approaches can introduce bias in data, and direct comparison of the results should be interpreted with caution. However, previous analyses demonstrated that PSR and ELISA methods significantly correlate in their capacity to identify polyreactive Abs (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). The validity of our results was also supported by the fact that there were considerable differences in the sequence patterns of V<sub>H</sub> determining polyreactivity in groups of Abs that were assessed by an identical polyreactivity assay (PSR). For example, note the differences between Abs from IgG+ memory B-cell group (n=146) and Abs from LLPC (n=143) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>).</p>
</sec>
<sec id="s2_4">
<title>Correlation analyses of sequence features of V<sub>H</sub> and V<sub>L</sub> regions determining the polyreactivity of Abs performed on integrated Ab repertoire</title>
<p>Next, we elucidated the sequence correlates of V regions that determine antigen-binding polyreactivity in an integrated set of Abs originating from different B-cell subpopulations. We excluded from this bulk repertoire only Abs originating from IgA+ B cells, as their polyreactivity was assessed by a different technique. By performing the statistical analyses of a panel of 398 Abs, a number of significant correlations were observed (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Thus, Ab polyreactivity in bulk repertoire correlated with the presence of a higher number of Arg residues in CDR H3 and a lower number of acidic amino acids (especially Glu) in the entire V<sub>H</sub> domain. Polyreactivity was also negatively correlated with Thr in CDR H1 and positively associated with the number of Gln residues in the whole V<sub>H</sub>. No significant correlation was observed between the number of hydrophobic amino acids in CDR loops of V<sub>H</sub> domain and the polyreactivity of Abs. Notably, higher polyreactivity of Abs correlated with an increased number of aromatic residues (Phe and Trp) in CDR H3 (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). The number of aromatic residues in FR1 was also significantly elevated in Abs with higher antigen-binding polyreactivity.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Correlation analyses of polyreactivity of human Abs cloned from different B-cell subpopulations with sequence characteristics of V<sub>H</sub> and V<sub>L</sub> domains. The heat maps present correlation coefficient (&#x3c1;) obtained by Spearman&#x2019;s rank analyses of sequences characteristics of V<sub>H</sub> (left panel) and V<sub>L</sub> (right panel) domains with the extent of the antigen-binding polyreactivity. Analyses were performed on integrated Ab repertoire consisting of Abs isolated from naive, IgM+ memory, IgG+ memory, and long-lived plasma cells. The blue color signifies a negative correlation; the red color signifies a positive correlation. The statistical significance (p-value) is indicated by a circle. Open circle p &lt; 0.05; semi-closed circle p &lt; 0.01, and closed circle p &lt; 0.005.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1266668-g003.tif"/>
</fig>
<p>The correlation analyses revealed even a larger number of significant correlations of V<sub>L</sub> sequence characteristics with the polyreactivity in bulk Ab repertoire (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Thus, a positive correlation was observed between the length of V<sub>L</sub> region and particularly of CDR L1 and promiscuous antigen binding. In addition, the number of polar amino acids in the V<sub>L</sub> or in CDR L1 and L3 correlated positively (Tyr and Thr) or negatively (Gln) with the Ab polyreactivity. The presence of the hydrophobic amino acid Val in the entire V<sub>L</sub> and in CDR L1 and L2 was similarly significantly associated with increased polyreactivity of Abs. However, the presence of Ile in whole V<sub>L</sub> and Ala in CDR L2 had a significantly negative impact on the Ab promiscuity (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). Similarly, as in the case of V<sub>H</sub>, polyreactivity of Abs in integrated Ab repertoire positively correlated with the presence of aromatic amino acid residues in CDR L1 (Tyr), CDR L2 (Trp), and in CDR L3 (as type). Polyreactivity of Abs also significantly correlated with an increased number of Gly residues in V<sub>L</sub> as well as in CDR L3 (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<p>Our analyses demonstrated that the FW regions of light-chain V regions have a more decisive role in determining polyreactivity in integrated Ab repertoire as compared with the FW region of heavy V regions (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). This observation suggests that a larger set of V<sub>L</sub> genes may be associated with the polyreactivity of Abs.</p>
<p>Collectively, these results revealed several significant correlates of Ab polyreactivity in bulk immune repertoire consisting of Abs from distinct B-cell subpopulations. These data showed certain prominent sequence patterns associated with polyreactivity&#x2014;lack of acidic residues in V<sub>H</sub> and presence of aromatic amino acids in CDRs of both V<sub>H</sub> and V<sub>L</sub>. The sequence pattern correlating with polyreactivity in bulk repertoire differed from the patterns in Abs from a particular B-cell subtype. Moreover, the strength of correlations was diminished, suggesting the presence of multiple pathways for the achievement of polyreactive antigen binding.</p>
</sec>
<sec id="s2_5">
<title>Analyses of Abs manifesting the highest level of antigen-binding polyreactivity</title>
<p>To obtain further information about molecular correlates of polyreactivity, we next focused our analyses only on Abs demonstrating the most prominent antigen-binding promiscuity. To this end, we selected the top 5 polyreactive Abs from each B-cell subpopulation. <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> presents a summary of the characteristics of the variable regions of the Abs. These data revealed that the most polyreactive Abs did not have any specific bias in the lengths of CDR loops or their isoelectric points. Thus, CDR H3 and CDR L1 regions displayed the highest variability of lengths among different polyreactive Abs, i.e., 8&#x2013;26 and 6&#x2013;12 residues for CDR H3 and CDR L1, respectively (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). <italic>In silico</italic> calculated isoelectric points of CDRs also varied in a very broad range between different Ab molecules (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). For example, in the case of the most diverse and important region for antigen recognition (CDR H3), the calculated pI values of the strongly polyreactive Abs were in the range between 3.67 and 9.14. It is noteworthy that substantial variability in the length of CDR loops and the pI values was observed between Abs within all groups, except in the case of Abs isolated from IgA+ B cells (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). These data indicate that a substantial level of antigen-binding promiscuity can be achieved by alternative topological and physicochemical features of the antigen-binding sites.</p>
<p>Furthermore, to gain more detailed information about the topology of the antigen-binding sites of polyreactive Abs, we applied the structural modeling algorithm Rosie-2 (Rosetta Commons). The side views of the most probable structures of V regions of Abs are shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>. These models demonstrated that the highly polyreactive human Abs have diverse topologies of their variable regions. One apparent feature observed in a part of the Abs is the presence of long and protruding CDR H3 (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). This structural feature was especially evident in polyreactive Abs from naive B cells (ADI-45498), IgM+ memory B cells (ADI-45499, ADI-45497), and LLPC (ADI-47276 and ADI-47265) and well corresponded to the length of CDR H3 (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). Interestingly, the structural models also indicated that some Abs have projecting only CDR L1 (ADI-45435, ADI-45430, and ADI-47275), or in some cases, both CDR H3 and CDR L1 are protruding (ADI-45435). Despite this obvious structural feature of variable regions of some of the polyreactive Abs, the structural models also showed that another fraction of highly polyreactive Abs did not display abnormally protruding CDR loops (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). Indeed, the topology of their binding sites is similar as the one depicted for most of the protein-binding Abs available in Ab structural databases. This observation further substantiated our results from correlation analyses, suggesting that polyreactive Abs use diverse pathways for the achievement of broad antigen-binding promiscuity.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Molecular models of V regions of polyreactive Abs. Molecular models of the Abs that manifest the highest level of antigen-binding polyreactivity from each B-cell category. The Abs were ordered according to the level of polyreactivity (PSR score, except for IgA+ memory B cells group) in descending order from left to right. Side view of the V region is presented. The blue ribbon corresponds to V<sub>H</sub>; the orange ribbon corresponds to V<sub>L</sub>. The models were generated with the Rosie-2 Ab-module of the Rosetta online server and visualized by the molecular viewer UCSF Chimera software v. 1.16.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1266668-g004.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Characteristics of top polyreactive antibodies used for molecular modeling analyses.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" rowspan="2" align="left">Origin / B cell subset</th>
<th valign="middle" rowspan="2" align="center">Antibody</th>
<th valign="middle" rowspan="2" align="center">Polyreactivity score*</th>
<th valign="middle" rowspan="2" align="center">VH mutation number</th>
<th valign="middle" colspan="2" align="center">CDRH1</th>
<th valign="middle" colspan="2" align="center">CDRH2</th>
<th valign="middle" colspan="2" align="center">CDRH3</th>
<th valign="middle" rowspan="2" align="center">VL mutation number</th>
<th valign="middle" colspan="2" align="center">CDRL1</th>
<th valign="middle" colspan="2" align="center">CDRL2</th>
<th valign="middle" colspan="2" align="center">CDRL3</th>
</tr>
<tr>
<th valign="middle" align="center">Length (a.a.)</th>
<th valign="top" align="center">Isoelectric point</th>
<th valign="middle" align="center">Length (a.a.)</th>
<th valign="top" align="center">Isoelectric point</th>
<th valign="middle" align="center">Length (a.a.)</th>
<th valign="top" align="center">Isoelectric point</th>
<th valign="middle" align="center">Length (a.a.)</th>
<th valign="top" align="center">Isoelectric point</th>
<th valign="middle" align="center">Length (a.a.)</th>
<th valign="top" align="center">Isoelectric point</th>
<th valign="middle" align="center">Length (a.a.)</th>
<th valign="top" align="center">Isoelectric point</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="background-color:#fef2cc">Naive</td>
<td valign="middle" align="center" style="background-color:#fef2cc">ADI-45498</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0,71069496</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.641</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.476</td>
<td valign="middle" align="center" style="background-color:#fef2cc">19</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8.110</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.955</td>
<td valign="middle" align="center" style="background-color:#fef2cc">3</td>
<td valign="middle" align="center" style="background-color:#fef2cc">3.596</td>
<td valign="middle" align="center" style="background-color:#fef2cc">11</td>
<td valign="middle" align="center" style="background-color:#fef2cc">3.604</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#fef2cc">Naive</td>
<td valign="middle" align="center" style="background-color:#fef2cc">ADI-45435</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0,457177329</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.741</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.067</td>
<td valign="middle" align="center" style="background-color:#fef2cc">20</td>
<td valign="middle" align="center" style="background-color:#fef2cc">6.131</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">12</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.992</td>
<td valign="middle" align="center" style="background-color:#fef2cc">3</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.861</td>
<td valign="middle" align="center" style="background-color:#fef2cc">9</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.956</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#fef2cc">Naive</td>
<td valign="middle" align="center" style="background-color:#fef2cc">ADI-45433</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0,364564497</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.708</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">6.054</td>
<td valign="middle" align="center" style="background-color:#fef2cc">17</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.065</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">11</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.141</td>
<td valign="middle" align="center" style="background-color:#fef2cc">3</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.697</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.105</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#fef2cc">Naive</td>
<td valign="middle" align="center" style="background-color:#fef2cc">ADI-45430</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0,260866421</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">9</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.744</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.040</td>
<td valign="middle" align="center" style="background-color:#fef2cc">14</td>
<td valign="middle" align="center" style="background-color:#fef2cc">4.090</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">12</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.992</td>
<td valign="middle" align="center" style="background-color:#fef2cc">3</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.861</td>
<td valign="middle" align="center" style="background-color:#fef2cc">9</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.937</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#fef2cc">Naive</td>
<td valign="middle" align="center" style="background-color:#fef2cc">ADI-46713</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0,19010429</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.620</td>
<td valign="middle" align="center" style="background-color:#fef2cc">8</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.646</td>
<td valign="middle" align="center" style="background-color:#fef2cc">12</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7.850</td>
<td valign="middle" align="center" style="background-color:#fef2cc">0</td>
<td valign="middle" align="center" style="background-color:#fef2cc">7</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.760</td>
<td valign="middle" align="center" style="background-color:#fef2cc">3</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.811</td>
<td valign="middle" align="center" style="background-color:#fef2cc">9</td>
<td valign="middle" align="center" style="background-color:#fef2cc">5.866</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e2efd9">IgM memory</td>
<td valign="middle" align="center" style="background-color:#e2efd9">ADI-45499</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0,710238077</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.620</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">6.054</td>
<td valign="middle" align="center" style="background-color:#e2efd9">23</td>
<td valign="middle" align="center" style="background-color:#e2efd9">7.360</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0</td>
<td valign="middle" align="center" style="background-color:#e2efd9">7</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.760</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.811</td>
<td valign="middle" align="center" style="background-color:#e2efd9">10</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.892</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e2efd9">IgM memory</td>
<td valign="middle" align="center" style="background-color:#e2efd9">ADI-47273</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0,263842045</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.834</td>
<td valign="middle" align="center" style="background-color:#e2efd9">7</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.745</td>
<td valign="middle" align="center" style="background-color:#e2efd9">14</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3.780</td>
<td valign="middle" align="center" style="background-color:#e2efd9">6</td>
<td valign="middle" align="center" style="background-color:#e2efd9">6</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.815</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8.073</td>
<td valign="middle" align="center" style="background-color:#e2efd9">9</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.942</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e2efd9">IgM memory</td>
<td valign="middle" align="center" style="background-color:#e2efd9">ADI-45487</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0,248689858</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.810</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3.544</td>
<td valign="middle" align="center" style="background-color:#e2efd9">16</td>
<td valign="middle" align="center" style="background-color:#e2efd9">4.038</td>
<td valign="middle" align="center" style="background-color:#e2efd9">1</td>
<td valign="middle" align="center" style="background-color:#e2efd9">7</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.760</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.811</td>
<td valign="middle" align="center" style="background-color:#e2efd9">9</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.867</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e2efd9">IgM memory</td>
<td valign="middle" align="center" style="background-color:#e2efd9">ADI-45497</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0,212869931</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.741</td>
<td valign="middle" align="center" style="background-color:#e2efd9">7</td>
<td valign="middle" align="center" style="background-color:#e2efd9">7.067</td>
<td valign="middle" align="center" style="background-color:#e2efd9">22</td>
<td valign="middle" align="center" style="background-color:#e2efd9">4.640</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0</td>
<td valign="middle" align="center" style="background-color:#e2efd9">6</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.650</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.885</td>
<td valign="middle" align="center" style="background-color:#e2efd9">9</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8.247</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e2efd9">IgM memory</td>
<td valign="middle" align="center" style="background-color:#e2efd9">ADI-45495</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0,151349728</td>
<td valign="middle" align="center" style="background-color:#e2efd9">0</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.760</td>
<td valign="middle" align="center" style="background-color:#e2efd9">7</td>
<td valign="middle" align="center" style="background-color:#e2efd9">5.745</td>
<td valign="middle" align="center" style="background-color:#e2efd9">12</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8.137</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8</td>
<td valign="middle" align="center" style="background-color:#e2efd9">9</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3.644</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3</td>
<td valign="middle" align="center" style="background-color:#e2efd9">3.606</td>
<td valign="middle" align="center" style="background-color:#e2efd9">10</td>
<td valign="middle" align="center" style="background-color:#e2efd9">8.165</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#deeaf6">IgG memory</td>
<td valign="middle" align="center" style="background-color:#deeaf6">ADI-47258</td>
<td valign="middle" align="center" style="background-color:#deeaf6">0,309315889</td>
<td valign="middle" align="center" style="background-color:#deeaf6">11</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">7.151</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3.746</td>
<td valign="middle" align="center" style="background-color:#deeaf6">19</td>
<td valign="middle" align="center" style="background-color:#deeaf6">4.247</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9</td>
<td valign="middle" align="center" style="background-color:#deeaf6">12</td>
<td valign="middle" align="center" style="background-color:#deeaf6">7.981</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.861</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8.210</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#deeaf6">IgG memory</td>
<td valign="middle" align="center" style="background-color:#deeaf6">ADI-47301</td>
<td valign="middle" align="center" style="background-color:#deeaf6">0,276256988</td>
<td valign="middle" align="center" style="background-color:#deeaf6">6</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8.143</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.651</td>
<td valign="middle" align="center" style="background-color:#deeaf6">12</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8.214</td>
<td valign="middle" align="center" style="background-color:#deeaf6">2</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3.644</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3.635</td>
<td valign="middle" align="center" style="background-color:#deeaf6">10</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.915</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#deeaf6">IgG memory</td>
<td valign="middle" align="center" style="background-color:#deeaf6">ADI-47300</td>
<td valign="middle" align="center" style="background-color:#deeaf6">0,237031082</td>
<td valign="middle" align="center" style="background-color:#deeaf6">7</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">7.142</td>
<td valign="middle" align="center" style="background-color:#deeaf6">7</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.793</td>
<td valign="middle" align="center" style="background-color:#deeaf6">19</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9.139</td>
<td valign="middle" align="center" style="background-color:#deeaf6">4</td>
<td valign="middle" align="center" style="background-color:#deeaf6">6</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.714</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8.073</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.930</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#deeaf6">IgG memory</td>
<td valign="middle" align="center" style="background-color:#deeaf6">ADI-47253</td>
<td valign="middle" align="center" style="background-color:#deeaf6">0,23696223</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.761</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3.598</td>
<td valign="middle" align="center" style="background-color:#deeaf6">14</td>
<td valign="middle" align="center" style="background-color:#deeaf6">4.091</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9</td>
<td valign="middle" align="center" style="background-color:#deeaf6">6</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.719</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.885</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.880</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#deeaf6">IgG memory</td>
<td valign="middle" align="center" style="background-color:#deeaf6">ADI-45432</td>
<td valign="middle" align="center" style="background-color:#deeaf6">0,222241241</td>
<td valign="middle" align="center" style="background-color:#deeaf6">16</td>
<td valign="middle" align="center" style="background-color:#deeaf6">8</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3.612</td>
<td valign="middle" align="center" style="background-color:#deeaf6">7</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3.625</td>
<td valign="middle" align="center" style="background-color:#deeaf6">26</td>
<td valign="middle" align="center" style="background-color:#deeaf6">4.521</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5</td>
<td valign="middle" align="center" style="background-color:#deeaf6">12</td>
<td valign="middle" align="center" style="background-color:#deeaf6">7.992</td>
<td valign="middle" align="center" style="background-color:#deeaf6">3</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.861</td>
<td valign="middle" align="center" style="background-color:#deeaf6">9</td>
<td valign="middle" align="center" style="background-color:#deeaf6">5.929</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#f8dcd8">IgA memory</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">1-208</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">4</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">15</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.753</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.683</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">15</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6.117</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">13</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">4.089</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.885</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">9</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6.044</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#f8dcd8">IgA memory</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">1-211</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">4</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">15</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3.497</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">7</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.868</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">12</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8.101</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">15</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6.905</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.775</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">9</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8.269</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#f8dcd8">IgA memory</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">1-235</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">4</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">7</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.820</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3.617</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">14</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6.297</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8.268</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.885</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">9</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.781</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#f8dcd8">IgA memory</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">1-239</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">4</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">12</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.716</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.879</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8.311</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">4</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.721</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.811</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">9</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3.651</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#f8dcd8">IgA memory</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">1-253</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">4</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">13</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.817</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">8</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.886</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">14</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">6.110</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">7</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.674</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">3</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.885</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">10</td>
<td valign="middle" align="center" style="background-color:#f8dcd8">5.920</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e6d3e7">LLPCs</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">ADI-47276</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">0,567042536</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">27</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.873</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">6.259</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">22</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">7.917</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">11</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">6</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.807</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8.073</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">9</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">7.123</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e6d3e7">LLPCs</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">ADI-47265</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">0,487816941</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">16</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.834</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.958</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">23</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">7.808</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">7</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.663</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.811</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">10</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.947</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e6d3e7">LLPCs</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">ADI-47275</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">0,4180419</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">24</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.815</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.802</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">11</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">4.041</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">12</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8.062</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.861</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">9</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8.295</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e6d3e7">LLPCs</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">ADI-47090</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">0,24495424</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">15</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">4.042</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8.256</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">18</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3.670</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">7</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3.559</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3.569</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">11</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3.626</td>
</tr>
<tr>
<td valign="middle" align="left" style="background-color:#e6d3e7">LLPCs</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">ADI-47303</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">0,201395637</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">18</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3.581</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8.618</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">12</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">7.112</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">10</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">7</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">8.574</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">5.774</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">9</td>
<td valign="middle" align="center" style="background-color:#e6d3e7">3.609</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>*For antibodies cloned from na&#xef;ve-, IgM+ memory-, IgG+ memory B cells and LLPC PSR scores are displayed as published in 27. For IgA+ memory B cells the polyreactivity was assessed by ELISA and Hep-assays. A numeric score 0-4 was assigned based on the number of recognized antigens and strength of the signal.The colors in Table 1 indicate different subsets of B cells from which studied antibodies originate.</p>
</table-wrap-foot>
</table-wrap>
<p>Polyreactivity has been associated with specific physiochemical characteristics of antigen-binding sites of Abs such as the presence of patches of positive charges on the molecular surface. To elucidate whether this is the case in the human Abs isolated from different B-cell compartments, we depicted the distribution of charges on the surface of antigen-binding sites of a selected set of Abs characterized with outstanding polyreactivity (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>). We also calculated three-dimensional Coulombic surface electrostatic potential of variable regions of the selected Abs (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>). These data demonstrated that different polyreactive Abs display distinct patterns of distribution of charged or non-polar residues in their binding sites (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>) and that the energy and space distribution of their electrostatic potentials differs substantially (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>). Some of the most polyreactive Abs, indeed, demonstrated extensive positively charged antigen-binding sites (for example, ADI-45498, ADI-46713, ADI-45499, ADI-47301, ADI-47300, and ADI-47303); moreover, the data revealed that a predominant fraction of Abs had antigen-binding surfaces deprived of negative charges. Nonetheless, there were highly polyreactive Abs with balanced positive and negative charged patches or in some cases; Abs had antigen-binding sites that carry little charged residues or even predominantly negative charges (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5</bold>
</xref>, <xref ref-type="fig" rid="f6">
<bold>6</bold>
</xref>).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Surface electrostatic coloring of the antigen binding sites of polyreactive Abs. Top view of the structures of V regions of the most polyreactive Abs, isolated from different B-cell subtypes. The V regions are ordered in descending order of their polyreactivity (from left to right). The structural models were generated by using the Rosie-2 Ab module of the Rosetta online server. Electrostatic charges (blue, positive; red, negative) were depicted by using UCSF Chimera software v. 1.16.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1266668-g005.tif"/>
</fig>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Three-dimensional electrostatic potential of V region of selected polyreactive Abs. Side view of the structural models of V regions of the most polyreactive Abs, isolated from different B-cell subtypes. The models were obtained by using the Rosie-2 Ab module of the Rosetta online server. The V regions are ordered in descending order of their polyreactivity (from left to right). The pictures show Coulombic electrostatic potentials (blue, positive; red, negative) that were calculated and visualized by using Swiss-PdbViewer v. 4.1.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1266668-g006.tif"/>
</fig>
<p>To confirm and broaden these observations, we further analyzed the structural and physicochemical characteristics of polyreactive Abs that bind to an identical epitope. A large number of broadly neutralizing HIV-1 Abs (bNAbs) are known to manifest antigen-binding polyreactivity (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B52">52</xref>). The Abs b12, 12a21, 3BNC117, CH103, 45-46m2, and VRC07 all bind to the same region on the HIV-1 envelope protein, i.e., gp120 CD4 binding site and were reported to be polyreactive (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). Importantly, the structures of Fab regions of these Abs have been determined by X-ray analyses (<xref ref-type="bibr" rid="B54">54</xref>&#x2013;<xref ref-type="bibr" rid="B58">58</xref>). Our comparative analyses of the topology and the physiochemical properties of antigen-binding sites of a set of polyreactive bNAbs demonstrated that there is not a common structural pattern that could explain their promiscuous antigen binding. Thus, b12, 45-46m2, and VRC07 have long and protruding CDR H3 loops (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>), whereas other polyreactive bNAbs have short and less exposed CDR H3. The polyreactive bNAbs also substantially differ in their three-dimensional electrostatic potentials and in the distribution of charges in their antigen-binding sites (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>). Thus, Abs 45-46m2 and VRC07 have predominantly positively charged antigen-binding sites with a potent positive electrostatic potential. However, the positive patches could not explain the polyreactivity of b12, 12a21, and 3BNC117, as these Abs have a more balanced distribution of the positive and the negative charges in their antigen-binding sites (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>). These data corroborate the results from our analyses of the physicochemical properties of the <italic>in silico</italic> modeled structures of V regions of polyreactive Abs (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4</bold>
</xref>
<bold>&#x2013;</bold>
<xref ref-type="fig" rid="f6">
<bold>6</bold>
</xref>). Moreover, they indicate that even among the polyreactive Abs targeting the same region in antigen, there could be distinct molecular mechanisms for the attainment of promiscuous antigen binding.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Structures and physicochemical features of a set of polyreactive HIV-1 broadly neutralizing antibodies. Structures (side view), three-dimensional electrostatic potentials (side view), and surface electrostatic coloring (top view) of V regions of polyreactive bNAbs&#x2014;b12, 12a21, 3BNC117, CH103, 45-46m2, and VRC07. For visualization of the structures of V domains PDB files 2NY7, 4JPW, 4JPV, 4JAM, 4JKP, and 4OLU were used. The structures and surface distribution of the electrostatic charges (blue, positive; red, negative) were visualized by using UCSF Chimera software v. 1.16. The three-dimensional Coulombic electrostatic potentials (blue, positive; red, negative) were calculated and visualized by using Swiss-PdbViewer v. 4.1.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1266668-g007.tif"/>
</fig>
<p>Collectively, the data from this part of the study strongly suggest that the polyreactive Abs do not use universal topological or physiochemical qualities that determine the binding to multiple unrelated antigens. Rather, variable regions with diverse properties can endow Abs with binding promiscuity.</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we deciphered the sequence correlates in V<sub>H</sub> and V<sub>L</sub> regions determining polyreactivity of human Abs. Our data show that Abs originating from different B-cell subtypes rely on distinct sequence patterns for their promiscuous antigen binding. This finding suggests that the mechanism of promiscuous antigen binding might evolve during the immune response, and it might be tailored to specific physiological roles of diverse B-cell types. Our data confirmed some previously documented sequence determinants of polyreactivity, but they also highlighted several unrecognized ones. Furthermore, data from molecular modeling of V regions of selected Abs with the highest level of polyreactivity and some polyreactive HIV-1neutralizing Abs implied the existence of alternative mechanisms that govern the antigen-binding promiscuity. Our data might explain some contradictions in the literature regarding the role of specific sequence motifs or molecular features of V regions for polyreactivity.</p>
<p>To assess sequence traits of V domains associated with polyreactivity, we applied non-parametric correlation analyses (Spearman&#x2019;s rank order correlation) using sequence and antigen-binding data for &gt;600 human Abs, unbiased by selection for a particular antigen specificity. The advantage of this approach is that it evaluates the individual contribution for Ab polyreactivity of every amino acid residue (or type of residues) in all parts of the V domain (CDRs and FWs). As polyreactivity/monoreactivity of Abs is not a binary measure but rather spreads as a continuum of varying extents, the correlation analyses can reveal subtle details in the sequence determinants of antigen-binding promiscuity without the need for <italic>a priori</italic> grouping of Abs as polyreactive and monoreactive. A key aspect of this study is that we applied the correlation analyses not only to bulk Ab repertoires but also to groups of Abs stratified based on B-cell type from which they originate: naive, IgM+ memory, IgG+ memory, IgA+ memory, and long-lived plasma cells.</p>
<p>Our data showed that Abs originating from various human B-cell subpopulations have different sequence determinants of their polyreactivity, especially in their V<sub>H</sub> domain (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1</bold>
</xref>, <xref ref-type="fig" rid="f2">
<bold>2</bold>
</xref>). From analyzing the heatmaps depicted in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>, we can conclude that Abs rely on five major groups of sequence attributes for their polyreactivity&#x2014;i) an increased number of positively charged residues in CDRs, ii) a reduced number of negatively charged residues in the entire V<sub>H</sub> and CDRs, iii) an increased number of aromatic residues in V<sub>H</sub> and CDRs, iv) a reduced number of aromatic residues in CDR H1, v) an increased number of polar residues in V<sub>H</sub> and CDRs, and vi) an increased number of hydrophobic residues in V<sub>H</sub> and CDRs. Notably, our data indicated that different categories of Abs use unique combinations of these sequence features for achieving polyreactivity, and in some cases, polyreactivity correlates with contrasting among the groups sequence characteristics. For example, polyreactive Abs cloned from naive B cells rely on a higher number of positively charged residues in their CDR H2. Similarly, higher polyreactivity of Abs cloned from LLPC correlated with the presence of an increased number of positively charged residues in CDRs. However, the polyreactivity in this group of Abs is also associated with a significantly elevated number of aromatic residues in CDR H3. On the other hand, polyreactivity of Abs from IgG+ memory B cells correlated strongly with reduced numbers of negatively charged residues, an increased number of Arg in CDR H3, and an increased frequency of polar amino acid residues in V<sub>H</sub> and CDRs. In contrast to other categories, Abs from IgM+ memory B cells rely exclusively on aromatic residues for promiscuous antigen binding. Interestingly, a unique pattern was detected also for Abs from IgA+ memory B cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). Thus, polyreactivity of these Abs significantly correlated with the presence of a higher number of hydrophobic amino acid residues in V<sub>H</sub> and CDRs (Leu, Ile, and Met) and an increased length of CDR H3. The polyreactivity of Abs isolated from IgA+ B cells correlates with a significantly reduced number of aromatic residues in CDR and the tendency for a lower prevalence of positively charged residues.</p>
<p>The V<sub>L</sub> sequence characteristics that had a strong correlation with polyreactivity were the length of CDR L1 and the presence of aromatic residues in CDRs. Of note, these patterns were constantly present in V<sub>L</sub> domains of Abs from all groups with exception of Abs cloned from IgM+ and IgA+ memory B cells (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>). The elevated frequency of positively charged amino acid residues in V<sub>L</sub> significantly correlated with polyreactivity only in case of Abs cloned from naive B cells. The CDR L1 region displays the highest variability in size among the three CDR L loops. One can speculate that the longer CDR loops can contribute to higher conformational dynamics, thus promoting promiscuous antigen binding.</p>
<p>In addition to identified determinants in CDRs, the statistical analyses uncovered important correlations of different amino acids in FWs of V<sub>H</sub> and V<sub>L</sub> with polyreactivity. These correlations were especially pronounced in both V domains of Abs isolated from naive and IgM+ memory B cells. The association of sequence traits of FWs in unmutated or weakly mutated V regions with polyreactivity might indicate biased usage of specific genes encoding V domains. Indeed, the contribution of some V gene segments for polyreactivity has already been demonstrated in different Ab repertoires (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>A sequence attribute that has been associated with polyreactivity of Abs is the mutation load in V<sub>H</sub> and V<sub>L</sub> domains. However, in the literature, there is controversial evidence about the role of this attribute. Thus, some studies show that the percentage of polyreactive Abs is the highest among germ-line Abs, whereas other works demonstrated a higher prevalence of polyreactivity among Abs with mutated V regions (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>). Our analyses revealed that a low number of mutations in V<sub>H</sub> significantly correlates with polyreactivity of Abs cloned from IgM+ memory B cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). In contrast, the mutations in V<sub>H</sub> or V<sub>L</sub> do not show a significant correlation with binding promiscuity of human Abs that were cloned from the other types of B cells.</p>
<p>Previous works demonstrated an association of a higher number of positively charged amino acid residues in CDRs or the presence of positively charged patches with polyreactivity of Abs (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>). Our statistical analyses confirmed these reports, but they also clearly demonstrated that this is not the determinant of polyreactivity for all groups of Abs and that this is not the strongest polyreactivity determinant. Molecular modeling of electrostatic potentials (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5</bold>
</xref>, <xref ref-type="fig" rid="f6">
<bold>6</bold>
</xref>) of the highest polyreactive Abs also demonstrated that positive charges are not exclusively present in all V regions. The statistical analyses demonstrated that there are two additional drivers of polyreactivity&#x2014;increased prevalence of aromatic amino acids in CDRs of V<sub>H</sub> and V<sub>L</sub> and an increased hydrophobicity of CDRs. The former is the strongest correlate for polyreactivity present both in V<sub>H</sub> and V<sub>L</sub>. To the best of our knowledge, in the literature, there are no systemic observations linking the higher number of aromatic amino acids or hydrophobic amino acids (as in the case of positively charged residues) as drivers of polyreactivity. There, are however, sporadic reports showing the association of Trp, Val, and Phe with polyreactivity in artificial Ab libraries (<xref ref-type="bibr" rid="B34">34</xref>) and in the case of some engineered monoclonal broadly neutralizing HIV-1 Abs, where the introduction of single or few aromatic residues resulted in a dramatic gain of antigen-binding promiscuity (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B57">57</xref>). As a consequence of their specific physicochemical and steric properties, aromatic residues in CDR would provide a capacity of Abs to establish numerous interactions with different macromolecules (<xref ref-type="bibr" rid="B61">61</xref>&#x2013;<xref ref-type="bibr" rid="B63">63</xref>). A high level of hydrophobic patches also gives a particular pattern of promiscuity through binding with similar hydrophobic regions on other macromolecules (<xref ref-type="bibr" rid="B63">63</xref>).</p>
<p>The finding that Abs originating from different B-cell subpopulations have different sequence features that determine their polyreactivity might have important biological repercussions. These mechanisms may reflect different functional requirements of binding promiscuity for Abs from different B-cell subpopulations. Thus, the fact that Abs cloned from IgA+ memory B cells use mostly hydrophobic residues as determinants of polyreactivity may reflect that these Abs operate mainly at mucosal surfaces. Indeed, the important role of Ab promiscuity of mucosal IgA has been emphasized by various recent works (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>). We hypothesize that polyreactivity that rely on hydrophobicity is required for the function of mucosal IgA, as intestinal and respiratory epithelial surfaces are covered with a mucous layer that is strongly negatively charged (<xref ref-type="bibr" rid="B66">66</xref>). If polyreactivity of IgA was mediated by positively charged residues or patches in V regions as in other cases, these Abs would be restrained by binding to highly charged mucous and would not be able to interact with bacteria or other pathogens. The hydrophobicity of IgA may also be directing Abs for binding to hydrophobic motifs on the bacterial cell walls, preventing bacterial adhesion (<xref ref-type="bibr" rid="B67">67</xref>). On the other hand, the predominant role of aromatic residues for polyreactivity of IgM+ memory B cells may offer a capacity of these Abs to bind to repetitive polysaccharide epitopes, which are typical for T-cell-independent antigens. Indeed, aromatic amino acids are the main type of amino acids implicated in the recognition of glycans (<xref ref-type="bibr" rid="B68">68</xref>).</p>
<p>The length of CDR loops has been related to the polyreactivity of antibodies (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Indeed, a longer CDR would result in a higher probability for conformational flexibility and, as a consequence, adaptability to various epitopes that may result in autoreactivity and polyreactivity (<xref ref-type="bibr" rid="B69">69</xref>, <xref ref-type="bibr" rid="B70">70</xref>). The visualization of V regions of the most polyreactive Abs, indeed, demonstrated that some molecules have outstandingly longer CDR loops, especially CDR H3 and CDR L1 (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> and <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). However, many of the modeled Abs did not show longer than average CDRs. This result strongly suggests that albeit some polyreactive antibodies may use long CDRs and eventual extended structural dynamics of binding sites for achieving polyreactivity, this mechanism is not employed by all Abs able to bind multiple antigens.</p>
<p>In this study, we also compared structures of the V regions of a set of polyreactive HIV-1 bNAbs that were previously determined by X-ray crystallographic analyses (<xref ref-type="bibr" rid="B54">54</xref>&#x2013;<xref ref-type="bibr" rid="B58">58</xref>). The selected Abs target an identical region on gp120 (CD4 binding site). The comparison of the structural features of these Abs revealed alternative patterns of charge distributions and different overall topologies of their antigen-binding sites (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>). This observation further corroborates results from the molecular modeling of polyreactive Abs from healthy humans (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4</bold>
</xref>
<bold>&#x2013;</bold>
<xref ref-type="fig" rid="f6">
<bold>6</bold>
</xref>) and suggests that different physicochemical traits might determine the polyreactivity of Abs, even of those Abs binding with high affinities to an identical region in the antigen.</p>
<p>Finally, our study rises an important question of whether Abs using different molecular mechanisms of polyreactivity would display different biological activities. It is plausible that Abs that participate in the first line of defense against pathogens and the ones that contribute to the clearance of damaged cells employ distinct molecular mechanisms for their polyreactivity. Moreover, it remains unknown whether the negative impact of polyreactivity on therapeutic monoclonal Abs differs depending on the underlying molecular mechanism. To address these questions, appropriate animal models should be implemented where immune defense, anti-inflammatory, and pharmacokinetics of different types of polyreactive Abs should be compared.</p>
<p>In conclusion, this study provides evidence for the implications of different molecular mechanisms in the polyreactivity of human Abs. It also demonstrates that the sequence features that determine the polyreactivity of Abs depend strongly on the B-cell origin of Abs. Thus, the study contributes valuable information about polyreactivity during the evolution of the humoral immune response. Moreover, it reveals a number of important correlates of antigen-binding promiscuity that would be of use for the assessment of developability or engineering of therapeutic Abs.</p>
</sec>
<sec id="s4">
<title>Methods</title>
<sec id="s4_1">
<title>Antibody repertoires and correlation analyses</title>
<p>We used data sets from two studies (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B37">37</xref>) where polyreactivity of human monoclonal Abs was assessed. The study of Shehata et&#xa0;al. published the sequence information of all monoclonal Abs. The sequence information for Abs in the study of Prigent et&#xa0;al. was kindly provided by Dr. Hugo Mouquet (Institute Pasteur, Paris, France). Since the polyreactivity in the study of Prigent et&#xa0;al. was displayed in semi-quantitative value, we assigned numerical values based on the number of recognized antigens from the ELISA panel. Since the polyreactivity in the study of Prigent et&#xa0;al. was displayed in a semi-quantitative value, we assigned a polyreactivity score as based on the number of antigens for which each antibody was considered as reactive by authors (score ranking from 0 to 4 antigens)</p>
<p>The identification of CDR regions and assessment of the number of amino acid replacements in V domains was performed by IMGT/V-Quest alignment software (<ext-link ext-link-type="uri" xlink:href="https://www.imgt.org/">https://www.imgt.org/</ext-link>). The GRAVY index was determined with the GRAVY Calculator (<ext-link ext-link-type="uri" xlink:href="https://www.gravy-calculator.de">https://www.gravy-calculator.de</ext-link>).The polyreactivity of Abs was correlated with different features of variable regions&#x2014;the number of somatic mutations in V<sub>H</sub> and V<sub>L</sub> domains; the length of CDR loops; the number of charged, polar, aromatic, and hydrophobic residues in the CDR and FW regions; and the frequency of individual amino acid residues in the CDR and FW regions. The correlation analyses were performed by non-parametric Spearman&#x2019;s rank-order analysis using GraphPad Prism v.10 software (La Jolla, CA). A significant correlation was considered only with <italic>p</italic> value &#x2264; 0.05.</p>
</sec>
<sec id="s4_2">
<title>Modeling of V regions of top polyreactive Abs and calculation of Coulombic electrostatic potentials</title>
<p>For modeling structures of the V regions of selected Abs that manifested the highest level of antigen-binding polyreactivity, we applied Ab structure modeling algorithm&#x2014;RosettaAntibody3 (<xref ref-type="bibr" rid="B71">71</xref>&#x2013;<xref ref-type="bibr" rid="B74">74</xref>). The sequences of V regions were submitted to the Rossie-2 module of the Rosetta online server (<ext-link ext-link-type="uri" xlink:href="https://rosie.rosettacommons.org/">https://rosie.rosettacommons.org/</ext-link>). Relaxed three-dimensional models with lowest energy of coupled V<sub>H</sub> and V<sub>L</sub> domains were visualized by using the Chimera UCSF Chimera package. The same software was used for coloring the electrostatic charges of the molecular surfaces of the antibodies. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311) (<xref ref-type="bibr" rid="B75">75</xref>). The three-dimensional Coulombic electrostatic potential was calculated and visualized by using Swiss-PdbViewer v. 4.1, <ext-link ext-link-type="uri" xlink:href="http://www.expasy.org/spdbv/">http://www.expasy.org/spdbv/</ext-link> (<xref ref-type="bibr" rid="B76">76</xref>).</p>
<p>Structural coordinates of Fab fragments determined by X-ray crystallography were obtained from the protein data bank (<ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link>) for the following polyreactive HIV-1 bNAbs: b12, 12a21, 3BNC117, CH103, 45-46m2, and VRC07 (PDB files: 2NY7, 4JPW, 4JPV, 4JAM, 4JKP, and 4OLU, respectively). The structural configuration and the electrostatic properties of V regions of these Abs were visualized with the same software packages as indicated before.</p>
</sec>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>ML: Data curation, Formal Analysis, Investigation, Methodology, Visualization, Writing &#x2013; original draft. RL: Data curation, Formal Analysis, Visualization, Investigation, Writing &#x2013; original draft. JD: Conceptualization, Formal Analysis, Funding acquisition, Methodology, Supervision, Validation, Visualization, Writing &#x2013; original draft.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale (INSERM, France) and by grants from Agence Nationale de la Recherche (ANR-13-JCV1-006-01) and from the European Research Council (Project CoBABATI ERC-StG-678905), both to JD.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We are grateful to Dr. Hugo Mouquet (Pasteur Institute, Paris, France) for providing us with complete sequence information of antibodies cloned from IgA+ B cells and for fruitful discussions.</p>
</ack>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Notkins</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>Polyreactivity of antibody molecules</article-title>. <source>Trends Immunol</source> (<year>2004</year>) <volume>25</volume>(<issue>4</issue>):<page-range>174&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2004.02.004</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitrov</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Planchais</surname> <given-names>C</given-names>
</name>
<name>
<surname>Roumenina</surname> <given-names>LT</given-names>
</name>
<name>
<surname>Vassilev</surname> <given-names>TL</given-names>
</name>
<name>
<surname>Kaveri</surname> <given-names>SV</given-names>
</name>
<name>
<surname>Lacroix-Desmazes</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Antibody polyreactivity in health and disease: statu variabilis</article-title>. <source>J Immunol</source> (<year>2013</year>) <volume>191</volume>(<issue>3</issue>):<page-range>993&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1300880</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname> <given-names>D</given-names>
</name>
<name>
<surname>Salunke</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Antibody specificity and promiscuity</article-title>. <source>Biochem J</source> (<year>2019</year>) <volume>476</volume>(<issue>3</issue>):<page-range>433&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/BCJ20180670</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boes</surname> <given-names>M</given-names>
</name>
<name>
<surname>Prodeus</surname> <given-names>AP</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>T</given-names>
</name>
<name>
<surname>Carroll</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection</article-title>. <source>J Exp Med</source> (<year>1998</year>) <volume>188</volume>(<issue>12</issue>):<page-range>2381&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.188.12.2381</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ochsenbein</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Fehr</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lutz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Suter</surname> <given-names>M</given-names>
</name>
<name>
<surname>Brombacher</surname> <given-names>F</given-names>
</name>
<name>
<surname>Hengartner</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Control of early viral and bacterial distribution and disease by natural antibodies</article-title>. <source>Science</source> (<year>1999</year>) <volume>286</volume>(<issue>5447</issue>):<page-range>2156&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.286.5447.2156</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>ZH</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>YF</given-names>
</name>
<name>
<surname>Wahl</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Cisar</surname> <given-names>JO</given-names>
</name>
<name>
<surname>Notkins</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies</article-title>. <source>Cell Host Microbe</source> (<year>2007</year>) <volume>1</volume>(<issue>1</issue>):<fpage>51</fpage>&#x2013;<lpage>61</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.chom.2007.01.002</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fransen</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zagato</surname> <given-names>E</given-names>
</name>
<name>
<surname>Mazzini</surname> <given-names>E</given-names>
</name>
<name>
<surname>Fosso</surname> <given-names>B</given-names>
</name>
<name>
<surname>Manzari</surname> <given-names>C</given-names>
</name>
<name>
<surname>El Aidy</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>BALB/c and C57BL/6 mice differ in polyreactive igA abundance, which impacts the generation of antigen-specific igA and microbiota diversity</article-title>. <source>Immunity</source> (<year>2015</year>) <volume>43</volume>(<issue>3</issue>):<page-range>527&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2015.08.011</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bunker</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Erickson</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Flynn</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Henry</surname> <given-names>C</given-names>
</name>
<name>
<surname>Koval</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Meisel</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Natural polyreactive IgA antibodies coat intestinal microbiota.</article-title> <source>Sci</source> (<year>2017</year>) <volume>358</volume>(<issue>6361</issue>):<elocation-id>eaan6619</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aan6619</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Rice</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Bannock</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Bielecka</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Strauss</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Catanzaro</surname> <given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Autoreactivity in naive human fetal B cells is associated with commensal bacteria recognition</article-title>. <source>Science</source> (<year>2020</year>) <volume>369</volume>(<issue>6501</issue>):<page-range>320&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aay9733</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haynes</surname> <given-names>BF</given-names>
</name>
<name>
<surname>Fleming</surname> <given-names>J</given-names>
</name>
<name>
<surname>St Clair</surname> <given-names>EW</given-names>
</name>
<name>
<surname>Katinger</surname> <given-names>H</given-names>
</name>
<name>
<surname>Stiegler</surname> <given-names>G</given-names>
</name>
<name>
<surname>Kunert</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies</article-title>. <source>Science</source> (<year>2005</year>) <volume>308</volume>(<issue>5730</issue>):<page-range>1906&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1111781</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mouquet</surname> <given-names>H</given-names>
</name>
<name>
<surname>Scheid</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Zoller</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Krogsgaard</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ott</surname> <given-names>RG</given-names>
</name>
<name>
<surname>Shukair</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation</article-title>. <source>Nature</source> (<year>2010</year>) <volume>467</volume>(<issue>7315</issue>):<page-range>591&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature09385</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Wiehe</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nicely</surname> <given-names>NI</given-names>
</name>
<name>
<surname>Vandergrift</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Rountree</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Polyreactivity and autoreactivity among HIV-1 antibodies</article-title>. <source>J Virol</source> (<year>2015</year>) <volume>89</volume>(<issue>1</issue>):<page-range>784&#x2013;98</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JVI.02378-14</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prigent</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jarossay</surname> <given-names>A</given-names>
</name>
<name>
<surname>Planchais</surname> <given-names>C</given-names>
</name>
<name>
<surname>Eden</surname> <given-names>C</given-names>
</name>
<name>
<surname>Dufloo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kok</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Conformational plasticity in broadly neutralizing HIV-1 antibodies triggers polyreactivity</article-title>. <source>Cell Rep</source> (<year>2018</year>) <volume>23</volume>(<issue>9</issue>):<page-range>2568&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.101</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bajic</surname> <given-names>G</given-names>
</name>
<name>
<surname>van der Poel</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Kuraoka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schmidt</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Carroll</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Kelsoe</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Autoreactivity profiles of influenza hemagglutinin broadly neutralizing antibodies</article-title>. <source>Sci Rep</source> (<year>2019</year>) <volume>9</volume>(<issue>1</issue>):<fpage>3492</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-019-40175-8</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guthmiller</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Lan</surname> <given-names>LY</given-names>
</name>
<name>
<surname>Fernandez-Quintero</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J</given-names>
</name>
<name>
<surname>Utset</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Bitar</surname> <given-names>DJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses</article-title>. <source>Immunity</source> (<year>2020</year>) <volume>53</volume>(<issue>6</issue>):<page-range>1230&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2020.10.005</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reyes-Ruiz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dimitrov</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>How can polyreactive antibodies conquer rapidly evolving viruses</article-title>? <source>Trends Immunol</source> (<year>2021</year>) <volume>42</volume>(<issue>8</issue>):<page-range>654&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2021.06.008</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname> <given-names>MY</given-names>
</name>
<name>
<surname>Fogelstrand</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hartvigsen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hansen</surname> <given-names>LF</given-names>
</name>
<name>
<surname>Woelkers</surname> <given-names>D</given-names>
</name>
<name>
<surname>Shaw</surname> <given-names>PX</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans</article-title>. <source>J Clin Invest</source> (<year>2009</year>) <volume>119</volume>(<issue>5</issue>):<page-range>1335&#x2013;49</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI36800</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrenstein</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Notley</surname> <given-names>CA</given-names>
</name>
</person-group>. <article-title>The importance of natural IgM: scavenger, protector and regulator</article-title>. <source>Nat Rev Immunol</source> (<year>2010</year>) <volume>10</volume>(<issue>11</issue>):<page-range>778&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2849</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>ZH</given-names>
</name>
<name>
<surname>Wild</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sylvers</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Polyreactive antibodies plus complement enhance the phagocytosis of cells made apoptotic by UV-light or HIV</article-title>. <source>Sci Rep</source> (<year>2013</year>) <volume>3</volume>:<elocation-id>2271</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/srep02271</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cunningham</surname> <given-names>O</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>ZS</given-names>
</name>
<name>
<surname>Finlay</surname> <given-names>WJJ</given-names>
</name>
</person-group>. <article-title>Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns</article-title>. <source>MAbs</source> (<year>2021</year>) <volume>13</volume>(<issue>1</issue>):<elocation-id>1999195</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/19420862.2021.1999195</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>T</given-names>
</name>
<name>
<surname>Durand</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hall</surname> <given-names>A</given-names>
</name>
<name>
<surname>Houston</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Nett</surname> <given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Biophysical properties of the clinical-stage antibody landscape</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2017</year>) <volume>114</volume>(<issue>5</issue>):<page-range>944&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1616408114</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jain</surname> <given-names>T</given-names>
</name>
<name>
<surname>Boland</surname> <given-names>T</given-names>
</name>
<name>
<surname>Vasquez</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches</article-title>. <source>MAbs</source> (<year>2023</year>) <volume>15</volume>(<issue>1</issue>):<elocation-id>2200540</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/19420862.2023.2200540</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wardemann</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yurasov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Schaefer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Young</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Meffre</surname> <given-names>E</given-names>
</name>
<name>
<surname>Nussenzweig</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Predominant autoantibody production by early human B cell precursors</article-title>. <source>Science</source> (<year>2003</year>) <volume>301</volume>(<issue>5638</issue>):<page-range>1374&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1086907</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiller</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tsuiji</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yurasov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Velinzon</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nussenzweig</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Wardemann</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Autoreactivity in human IgG+ memory B cells</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>26</volume>(<issue>2</issue>):<page-range>205&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2007.01.009</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birtalan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fellouse</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Schaefer</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sidhu</surname> <given-names>SS</given-names>
</name>
</person-group>. <article-title>The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies</article-title>. <source>J Mol Biol</source> (<year>2008</year>) <volume>377</volume>(<issue>5</issue>):<page-range>1518&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jmb.2008.01.093</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiller</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Julian</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Garde</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tessier</surname> <given-names>PM</given-names>
</name>
</person-group>. <article-title>Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs</article-title>. <source>J Biol Chem</source> (<year>2017</year>) <volume>292</volume>(<issue>40</issue>):<page-range>16638&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.M117.783837</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shehata</surname> <given-names>L</given-names>
</name>
<name>
<surname>Maurer</surname> <given-names>DP</given-names>
</name>
<name>
<surname>Wec</surname> <given-names>AZ</given-names>
</name>
<name>
<surname>Lilov</surname> <given-names>A</given-names>
</name>
<name>
<surname>Champney</surname> <given-names>E</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Affinity maturation enhances antibody specificity but compromises conformational stability</article-title>. <source>Cell Rep</source> (<year>2019</year>) <volume>28</volume>(<issue>13</issue>):<page-range>3300&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2019.08.056</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname> <given-names>YD</given-names>
</name>
<name>
<surname>Pegu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>ES</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Bender</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Asokan</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain</article-title>. <source>MAbs</source> (<year>2023</year>) <volume>15</volume>(<issue>1</issue>):<elocation-id>2223350</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/19420862.2023.2223350</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Datta-Mannan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Thangaraju</surname> <given-names>A</given-names>
</name>
<name>
<surname>Leung</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Witcher</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics</article-title>. <source>MAbs</source> (<year>2015</year>) <volume>7</volume>(<issue>3</issue>):<page-range>483&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/19420862.2015.1016696</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoch</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kettenberger</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mundigl</surname> <given-names>O</given-names>
</name>
<name>
<surname>Winter</surname> <given-names>G</given-names>
</name>
<name>
<surname>Engert</surname> <given-names>J</given-names>
</name>
<name>
<surname>Heinrich</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2015</year>) <volume>112</volume>(<issue>19</issue>):<fpage>5997</fpage>&#x2013;<lpage>6002</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1408766112</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabia</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ludwig</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Julian</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Tessier</surname> <given-names>PM</given-names>
</name>
</person-group>. <article-title>Net charge of antibody complementarity-determining regions is a key predictor of specificity</article-title>. <source>Protein Eng Des Sel</source> (<year>2018</year>) <volume>31</volume>(<issue>11</issue>):<page-range>409&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/protein/gzz002</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecerf</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kanyavuz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lacroix-Desmazes</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dimitrov</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies</article-title>. <source>Mol Immunol</source> (<year>2019</year>) <volume>112</volume>:<page-range>338&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2019.06.012</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raybould</surname> <given-names>MIJ</given-names>
</name>
<name>
<surname>Marks</surname> <given-names>C</given-names>
</name>
<name>
<surname>Krawczyk</surname> <given-names>K</given-names>
</name>
<name>
<surname>Taddese</surname> <given-names>B</given-names>
</name>
<name>
<surname>Nowak</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lewis</surname> <given-names>AP</given-names>
</name>
<etal/>
</person-group>. <article-title>Five computational developability guidelines for therapeutic antibody profiling</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2019</year>) <volume>116</volume>(<issue>10</issue>):<page-range>4025&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1810576116</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Le</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wittrup</surname> <given-names>KD</given-names>
</name>
</person-group>. <article-title>Reduction of nonspecificity motifs in synthetic antibody libraries</article-title>. <source>J Mol Biol</source> (<year>2018</year>) <volume>430</volume>(<issue>1</issue>):<page-range>119&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jmb.2017.11.008</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boughter</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Borowska</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Guthmiller</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Bendelac</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Roux</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Biochemical patterns of antibody polyreactivity revealed through a bioinformatics-based analysis of CDR loops</article-title>. <source>Elife</source> (<year>2020</year>) <volume>9</volume>:<elocation-id>e61393</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.7554/eLife.61393</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berkowska</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Schickel</surname> <given-names>JN</given-names>
</name>
<name>
<surname>Grosserichter-Wagener</surname> <given-names>C</given-names>
</name>
<name>
<surname>de Ridder</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ng</surname> <given-names>YS</given-names>
</name>
<name>
<surname>van Dongen</surname> <given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Circulating human CD27-igA+ Memory B cells recognize bacteria with polyreactive igs</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>195</volume>(<issue>4</issue>):<page-range>1417&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1402708</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prigent</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lorin</surname> <given-names>V</given-names>
</name>
<name>
<surname>Kok</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hieu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bourgeau</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mouquet</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Scarcity of autoreactive human blood IgA(+) memory B cells</article-title>. <source>Eur J Immunol</source> (<year>2016</year>) <volume>46</volume>(<issue>10</issue>):<page-range>2340&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.201646446</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laffy</surname> <given-names>JMJ</given-names>
</name>
<name>
<surname>Dodev</surname> <given-names>T</given-names>
</name>
<name>
<surname>Macpherson</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Townsend</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Dunn-Walters</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Promiscuous antibodies characterised by their physico-chemical properties: From sequence to structure and back</article-title>. <source>Prog Biophys Mol Biol</source> (<year>2017</year>) <volume>128</volume>:<fpage>47</fpage>&#x2013;<lpage>56</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pbiomolbio.2016.09.002</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jaiswal</surname> <given-names>D</given-names>
</name>
<name>
<surname>Verma</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nair</surname> <given-names>DT</given-names>
</name>
<name>
<surname>Salunke</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Antibody multispecificity: A necessary evil</article-title>? <source>Mol Immunol</source> (<year>2022</year>) <volume>152</volume>:<page-range>153&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2022.10.012</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manivel</surname> <given-names>V</given-names>
</name>
<name>
<surname>Sahoo</surname> <given-names>NC</given-names>
</name>
<name>
<surname>Salunke</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>KV</given-names>
</name>
</person-group>. <article-title>Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site</article-title>. <source>Immunity</source> (<year>2000</year>) <volume>13</volume>(<issue>5</issue>):<page-range>611&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1074-7613(00)00061-3</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manivel</surname> <given-names>V</given-names>
</name>
<name>
<surname>Bayiroglu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Siddiqui</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Salunke</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>KV</given-names>
</name>
</person-group>. <article-title>The primary antibody repertoire represents a linked network of degenerate antigen specificities</article-title>. <source>J Immunol</source> (<year>2002</year>) <volume>169</volume>(<issue>2</issue>):<page-range>888&#x2013;97</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.169.2.888</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Beuscher</surname> <given-names>A</given-names>
</name>
<name>
<surname>Andryski</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Stevens</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Schultz</surname> <given-names>PG</given-names>
</name>
</person-group>. <article-title>Structural plasticity and the evolution of antibody affinity and specificity</article-title>. <source>J Mol Biol</source> (<year>2003</year>) <volume>330</volume>(<issue>4</issue>):<page-range>651&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0022-2836(03)00631-4</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Roversi</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tawfik</surname> <given-names>DS</given-names>
</name>
</person-group>. <article-title>Antibody multispecificity mediated by conformational diversity</article-title>. <source>Science</source> (<year>2003</year>) <volume>299</volume>(<issue>5611</issue>):<page-range>1362&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1079731</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jimenez</surname> <given-names>R</given-names>
</name>
<name>
<surname>Salazar</surname> <given-names>G</given-names>
</name>
<name>
<surname>Baldridge</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Romesberg</surname> <given-names>FE</given-names>
</name>
</person-group>. <article-title>Flexibility and molecular recognition in the immune system</article-title>. <source>Proc Natl Acad Sci USA</source> (<year>2003</year>) <volume>100</volume>(<issue>1</issue>):<page-range>92&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.262411399</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname> <given-names>HP</given-names>
</name>
<name>
<surname>Seto</surname> <given-names>NO</given-names>
</name>
<name>
<surname>MacKenzie</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Brade</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kosma</surname> <given-names>P</given-names>
</name>
<name>
<surname>Brade</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Germline antibody recognition of distinct carbohydrate epitopes</article-title>. <source>Nat Struct Biol</source> (<year>2003</year>) <volume>10</volume>(<issue>12</issue>):<page-range>1019&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nsb1014</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Salunke</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Adjustable locks and flexible keys: plasticity of epitope-paratope interactions in germline antibodies</article-title>. <source>J Immunol</source> (<year>2014</year>) <volume>192</volume>(<issue>11</issue>):<page-range>5398&#x2013;405</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1302143</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Quintero</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Loeffler</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Kraml</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kahler</surname> <given-names>U</given-names>
</name>
<name>
<surname>Kamenik</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Liedl</surname> <given-names>KR</given-names>
</name>
</person-group>. <article-title>Characterizing the diversity of the CDR-H3 loop conformational ensembles in relationship to antibody binding properties</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>3065</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.03065</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blackler</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Muller-Loennies</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pokorny-Lehrer</surname> <given-names>B</given-names>
</name>
<name>
<surname>Legg</surname> <given-names>MSG</given-names>
</name>
<name>
<surname>Brade</surname> <given-names>L</given-names>
</name>
<name>
<surname>Brade</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Antigen binding by conformational selection in near-germline antibodies</article-title>. <source>J Biol Chem</source> (<year>2022</year>) <volume>298</volume>(<issue>5</issue>):<elocation-id>101901</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jbc.2022.101901</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sethi</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Agarwal</surname> <given-names>A</given-names>
</name>
<name>
<surname>Manivel</surname> <given-names>V</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>KV</given-names>
</name>
<name>
<surname>Salunke</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response</article-title>. <source>Immunity</source> (<year>2006</year>) <volume>24</volume>(<issue>4</issue>):<page-range>429&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2006.02.010</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecerf</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kanyavuz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rossini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dimitrov</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Interaction of clinical-stage antibodies with heme predicts their physiochemical and binding qualities</article-title>. <source>Commun Biol</source> (<year>2021</year>) <volume>4</volume>(<issue>1</issue>):<fpage>391</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s42003-021-01931-7</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecerf</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lacombe</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kanyavuz</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dimitrov</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Functional changes of therapeutic antibodies upon exposure to pro-oxidative agents</article-title>. <source>Antibodies (Basel)</source> (<year>2022</year>) <volume>11</volume>(<issue>1</issue>):<fpage>11</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/antib11010011</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corti</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lanzavecchia</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Broadly neutralizing antiviral antibodies</article-title>. <source>Annu Rev Immunol</source> (<year>2013</year>) <volume>31</volume>:<page-range>705&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095916</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scheid</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Mouquet</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ueberheide</surname> <given-names>B</given-names>
</name>
<name>
<surname>Diskin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Klein</surname> <given-names>F</given-names>
</name>
<name>
<surname>Oliveira</surname> <given-names>TY</given-names>
</name>
<etal/>
</person-group>. <article-title>Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding</article-title>. <source>Science</source> (<year>2011</year>) <volume>333</volume>(<issue>6049</issue>):<page-range>1633&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1207227</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dey</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hessell</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Van Ryk</surname> <given-names>D</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>SH</given-names>
</name>
<etal/>
</person-group>. <article-title>Structural definition of a conserved neutralization epitope on HIV-1 gp120</article-title>. <source>Nature</source> (<year>2007</year>) <volume>445</volume>(<issue>7129</issue>):<page-range>732&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature05580</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klein</surname> <given-names>F</given-names>
</name>
<name>
<surname>Diskin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Scheid</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Gaebler</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mouquet</surname> <given-names>H</given-names>
</name>
<name>
<surname>Georgiev</surname> <given-names>IS</given-names>
</name>
<etal/>
</person-group>. <article-title>Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization</article-title>. <source>Cell</source> (<year>2013</year>) <volume>153</volume>(<issue>1</issue>):<page-range>126&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2013.03.018</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname> <given-names>HX</given-names>
</name>
<name>
<surname>Lynch</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>T</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Alam</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Boyd</surname> <given-names>SD</given-names>
</name>
<etal/>
</person-group>. <article-title>Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus</article-title>. <source>Nature</source> (<year>2013</year>) <volume>496</volume>(<issue>7446</issue>):<page-range>469&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature12053</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diskin</surname> <given-names>R</given-names>
</name>
<name>
<surname>Klein</surname> <given-names>F</given-names>
</name>
<name>
<surname>Horwitz</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Halper-Stromberg</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sather</surname> <given-names>DN</given-names>
</name>
<name>
<surname>Marcovecchio</surname> <given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies</article-title>. <source>J Exp Med</source> (<year>2013</year>) <volume>210</volume>(<issue>6</issue>):<page-range>1235&#x2013;49</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20130221</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudicell</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Kwon</surname> <given-names>YD</given-names>
</name>
<name>
<surname>Ko</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Pegu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Louder</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Georgiev</surname> <given-names>IS</given-names>
</name>
<etal/>
</person-group>. <article-title>Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in <italic>vivo</italic>
</article-title>. <source>J Virol</source> (<year>2014</year>) <volume>88</volume>(<issue>21</issue>):<page-range>12669&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JVI.02213-14</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>ZH</given-names>
</name>
<name>
<surname>Tzioufas</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Notkins</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells</article-title>. <source>J Autoimmun</source> (<year>2007</year>) <volume>29</volume>(<issue>4</issue>):<page-range>219&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jaut.2007.07.015</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname> <given-names>HX</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Munshaw</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Marshall</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Vandergrift</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated</article-title>. <source>J Exp Med</source> (<year>2011</year>) <volume>208</volume>(<issue>11</issue>):<page-range>2237&#x2013;49</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20110363</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gervasio</surname> <given-names>FL</given-names>
</name>
<name>
<surname>Chelli</surname> <given-names>R</given-names>
</name>
<name>
<surname>Procacci</surname> <given-names>P</given-names>
</name>
<name>
<surname>Schettino</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>The nature of intermolecular interactions between aromatic amino acid residues</article-title>. <source>Proteins</source> (<year>2002</year>) <volume>48</volume>(<issue>1</issue>):<page-range>117&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/prot.10116</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sundberg</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Mariuzza</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Molecular recognition in antibody-antigen complexes</article-title>. <source>Adv Protein Chem</source> (<year>2002</year>) <volume>61</volume>:<page-range>119&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0065-3233(02)61004-6</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ausserwoger</surname> <given-names>H</given-names>
</name>
<name>
<surname>Schneider</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Herling</surname> <given-names>TW</given-names>
</name>
<name>
<surname>Arosio</surname> <given-names>P</given-names>
</name>
<name>
<surname>Invernizzi</surname> <given-names>G</given-names>
</name>
<name>
<surname>Knowles</surname> <given-names>TPJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Non-specificity as the sticky problem in therapeutic antibody development</article-title>. <source>Nat Rev Chem</source> (<year>2022</year>) <volume>6</volume>(<issue>12</issue>):<page-range>844&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41570-022-00438-x</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bunker</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Bendelac</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>IgA responses to microbiota</article-title>. <source>Immunity</source> (<year>2018</year>) <volume>49</volume>(<issue>2</issue>):<page-range>211&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2018.08.011</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huus</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Petersen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Finlay</surname> <given-names>BB</given-names>
</name>
</person-group>. <article-title>Diversity and dynamism of IgA-microbiota interactions</article-title>. <source>Nat Rev Immunol</source> (<year>2021</year>) <volume>21</volume>(<issue>8</issue>):<page-range>514&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-021-00506-1</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leal</surname> <given-names>J</given-names>
</name>
<name>
<surname>Smyth</surname> <given-names>HDC</given-names>
</name>
<name>
<surname>Ghosh</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Physicochemical properties of mucus and their impact on transmucosal drug delivery</article-title>. <source>Int J Pharm</source> (<year>2017</year>) <volume>532</volume>(<issue>1</issue>):<page-range>555&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.09.018</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Loosdrecht</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Lyklema</surname> <given-names>J</given-names>
</name>
<name>
<surname>Norde</surname> <given-names>W</given-names>
</name>
<name>
<surname>Schraa</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zehnder</surname> <given-names>AJ</given-names>
</name>
</person-group>. <article-title>The role of bacterial cell wall hydrophobicity in adhesion</article-title>. <source>Appl Environ Microbiol</source> (<year>1987</year>) <volume>53</volume>(<issue>8</issue>):<page-range>1893&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/aem.53.8.1893-1897.1987</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hudson</surname> <given-names>KL</given-names>
</name>
<name>
<surname>Bartlett</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Diehl</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Agirre</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gallagher</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kiessling</surname> <given-names>LL</given-names>
</name>
<etal/>
</person-group>. <article-title>Carbohydrate-aromatic interactions in proteins</article-title>. <source>J Am Chem Soc</source> (<year>2015</year>) <volume>137</volume>(<issue>48</issue>):<page-range>15152&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/jacs.5b08424</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<elocation-id>250</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00250</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname> <given-names>WK</given-names>
</name>
<name>
<surname>Leem</surname> <given-names>J</given-names>
</name>
<name>
<surname>Deane</surname> <given-names>CM</given-names>
</name>
</person-group>. <article-title>Comparative analysis of the CDR loops of antigen receptors</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2454</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02454</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sivasubramanian</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sircar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chaudhury</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>JJ</given-names>
</name>
</person-group>. <article-title>Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking</article-title>. <source>Proteins</source> (<year>2009</year>) <volume>74</volume>(<issue>2</issue>):<fpage>497</fpage>&#x2013;<lpage>514</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/prot.22309</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marze</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Lyskov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>JJ</given-names>
</name>
</person-group>. <article-title>Improved prediction of antibody VL-VH orientation</article-title>. <source>Protein Eng Des Sel</source> (<year>2016</year>) <volume>29</volume>(<issue>10</issue>):<page-range>409&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/protein/gzw013</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weitzner</surname> <given-names>BD</given-names>
</name>
<name>
<surname>Jeliazkov</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Lyskov</surname> <given-names>S</given-names>
</name>
<name>
<surname>Marze</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kuroda</surname> <given-names>D</given-names>
</name>
<name>
<surname>Frick</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Modeling and docking of antibody structures with Rosetta</article-title>. <source>Nat Protoc</source> (<year>2017</year>) <volume>12</volume>(<issue>2</issue>):<page-range>401&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nprot.2016.180</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weitzner</surname> <given-names>BD</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>JJ</given-names>
</name>
</person-group>. <article-title>Accurate structure prediction of CDR H3 loops enabled by a novel structure-based C-terminal constraint</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>198</volume>(<issue>1</issue>):<page-range>505&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1601137</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname> <given-names>EF</given-names>
</name>
<name>
<surname>Goddard</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Couch</surname> <given-names>GS</given-names>
</name>
<name>
<surname>Greenblatt</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>EC</given-names>
</name>
<etal/>
</person-group>. <article-title>UCSF Chimera&#x2013;a visualization system for exploratory research and analysis</article-title>. <source>J Comput Chem</source> (<year>2004</year>) <volume>25</volume>(<issue>13</issue>):<page-range>1605&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guex</surname> <given-names>N</given-names>
</name>
<name>
<surname>Peitsch</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling</article-title>. <source>Electrophoresis</source> (<year>1997</year>) <volume>18</volume>(<issue>15</issue>):<page-range>2714&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/elps.1150181505</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>